Treatment targets in SLE: remission and low disease activity state
Author:
Affiliation:
1. School of Clinical Sciences, Monash University, Melbourne, VIC, Australia
2. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, the Netherlands
Abstract
Funder
GSK
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/article-pdf/59/Supplement_5/v19/34729973/keaa420.pdf
Reference67 articles.
1. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus;Furie;Arthritis Rheum,2011
2. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial;Navarra;Lancet,2011
3. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients;Cervera;Medicine,2003
4. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial;Verdecchia;Lancet,2009
5. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes;Nathan;N Engl J Med,2005
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The Impact of Systemic Lupus Erythematosus Flares on Clinical and Economic Outcomes: The CHAMOMILE Claims Database Study in Germany;Rheumatology and Therapy;2024-01-22
2. Gut microbiota landscape and potential biomarker identification in female patients with systemic lupus erythematosus using machine learning;Frontiers in Cellular and Infection Microbiology;2023-12-19
3. Assessment of disease activity and damage in SLE: Are we there yet?;Best Practice & Research Clinical Rheumatology;2023-12
4. Targeting DORIS Remission and LLDAS in SLE: A Review;Rheumatology and Therapy;2023-10-05
5. Selection of indicators reporting response rate in pharmaceutical trials for systemic lupus erythematosus: preference and relative sensitivity;Lupus Science & Medicine;2023-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3